Literature DB >> 10849370

CD4+ T cells of schistosomiasis naturally resistant individuals living in an endemic area produce interferon-gamma and tumour necrosis factor-alpha in response to the recombinant 14KDA Schistosoma mansoni fatty acid-binding protein.

C F Brito1, I R Caldas, P Coura Filho, R Correa-Oliveira, S C Oliveira.   

Abstract

Cellular immune responses to recombinant (r) Sm14 were examined in chronic, treated patients and uninfected individuals living in an endemic area for schistosomiasis. The lymphocyte proliferative responses and cytokine profile to this antigen were evaluated. Peripheral blood mononuclear cells (PBMC) of all groups studied proliferated to rSm14. However, the highest proliferation index to rSm14 was detected in uninfected endemic normal (EN) individuals who are naturally resistant to schistosomiasis. Regarding the cytokines produced, the levels of interleukin (IL)-5 and IL-10, known as Th2 cytokines, were not statistically different among all groups studied. In contrast, interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha were produced in significantly higher amounts by PBMC of EN individuals following rSm14 stimulation. Additionally, we have determined by flow cytometry that CD4+ T cells from these individuals are the main lymphocyte subpopulation producing IFN-gamma and TNF-alpha. Moreover, we have used rIL-10 or rIFN-gamma, or monoclonal antibodies (MoAb) against these two cytokines to determine their role on cellular reactivity to rSm14. Exogenous IL-10 suppressed T-cell proliferation and neutralization of endogenous IL-10 restored lymphocyte activation and enhanced IFN-gamma and TNF-alpha production in chronically infected patients. In contrast, the addition of anti-IFN-gamma totally abrogated the PBMC proliferation within the EN group. This study demonstrated that IL-10 is an important cytokine down-regulating T-cell responses in chronic schistosomiasis, whereas lymphocyte proliferation in the uninfected resistant group is dependent on IFN-gamma. Taken together these results suggest that Th1 type of immune response induced in EN individuals to a specific schistosome antigen might be associated with resistance to infection and also highlighted the importance of Sm14 as a potential vaccine candidate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10849370     DOI: 10.1046/j.1365-3083.2000.00710.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  18 in total

1.  Factors associated with resistance to Schistosoma mansoni infection in an endemic area of Bahia, Brazil.

Authors:  Ricardo R Oliveira; Joanemile P Figueiredo; Luciana S Cardoso; Rafael L Jabar; Robson P Souza; Martin T Wells; Edgar M Carvalho; Daniel W Fitzgerald; Kathleen C Barnes; Maria Ilma Araújo; Marshall J Glesby
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

Review 2.  Tissue-based class control: the other side of tolerance.

Authors:  Polly Matzinger; Tirumalai Kamala
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

3.  Cytokine patterns in experimental schistosomiasis mansoni infected mice treated with silymarin.

Authors:  Nagwa Mostafa El-Sayed; Ghada Mahmoud Fathy; Sara Abdel-Rahman Abdel-Rahman; Mahmoud Abdel-Atei El-Shafei
Journal:  J Parasit Dis       Date:  2014-10-30

Review 4.  Vaccines to combat the neglected tropical diseases.

Authors:  Jeffrey M Bethony; Rhea N Cole; Xiaoti Guo; Shaden Kamhawi; Marshall W Lightowlers; Alex Loukas; William Petri; Steven Reed; Jesus G Valenzuela; Peter J Hotez
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  Profile of T and B lymphocytes in individuals resistant to Schistosoma mansoni infection.

Authors:  Robson da Paixão de Souza; Maria Ilma Araújo; Diego Mota Lopes; Sérgio Costa Oliveira; Jamille Souza Fernandes; Kelvin Edson M de Jesus; Edgar M Carvalho; Ricardo Riccio Oliveira; Luciana Santos Cardoso
Journal:  Parasitol Res       Date:  2022-02-08       Impact factor: 2.289

6.  Cross-reactivity of Schistosoma mansoni cytosolic superoxide dismutase, a protective vaccine candidate, with host superoxide dismutase and identification of parasite-specific B epitopes.

Authors:  Claudia Carvalho-Queiroz; Rosemary Cook; Ching C Wang; Rodrigo Correa-Oliveira; Nicola A Bailey; Nejat K Egilmez; Edith Mathiowitz; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

7.  Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge.

Authors:  Paula B Varaldo; Luciana C C Leite; Waldely O Dias; Eliane N Miyaji; Fabio I G Torres; Vera C Gebara; Geraldo R G Armôa; Adriano S Campos; Denise C S Matos; Nathalie Winter; Brigitte Gicquel; Mônica M Vilar; Johnjoe McFadden; Marilia S Almeida; Miriam Tendler; Douglas McIntosh
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

8.  Cytokine Pattern of T Lymphocytes in Acute Schistosomiasis mansoni Patients following Treated Praziquantel Therapy.

Authors:  Denise Silveira-Lemos; Matheus Fernandes Costa-Silva; Amanda Cardoso de Oliveira Silveira; Mauricio Azevedo Batista; Lúcia Alves Oliveira-Fraga; Alda Maria Soares Silveira; Maria Carolina Barbosa Alvarez; Olindo Assis Martins-Filho; Giovanni Gazzinelli; Rodrigo Corrêa-Oliveira; Andréa Teixeira-Carvalho
Journal:  J Parasitol Res       Date:  2013-01-20

9.  Association of the gene polymorphisms IFN-gamma +874, IL-13 -1055 and IL-4 -590 with patterns of reinfection with Schistosoma mansoni.

Authors:  Michael R Gatlin; Carla L Black; Pauline N Mwinzi; W Evan Secor; Diana M Karanja; Daniel G Colley
Journal:  PLoS Negl Trop Dis       Date:  2009-02-03

10.  Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection.

Authors:  Fernanda C Cardoso; Gilson C Macedo; Elisandra Gava; Gregory T Kitten; Vitor L Mati; Alan L de Melo; Marcelo V Caliari; Giulliana T Almeida; Thiago M Venancio; Sergio Verjovski-Almeida; Sergio C Oliveira
Journal:  PLoS Negl Trop Dis       Date:  2008-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.